Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and disease progression, and could benefit from early antiviral treatment ...
A clinical trial led by Kirby Institute at UNSW Sydney has found that point-of-care testing for hepatitis B DNA is as effective as traditional laboratory testing, paving the way for faster diagnosis ...
In HepG2.117 cells, ALG-001075 achieved HBV DNA EC50 0.64 nM, outperforming canocapavir (5.8 nM) and neracorvir (24 nM) with ...
Preclinical data shows strong, durable, and precise repression of HBV DNA across in vitro and in vivo models, offering a possible pathway to a functional cure DURHAM, N.C. & SEATTLE--(BUSINESS ...
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other ...
Tune Therapeutics, a leading epigenome editing company, presented new data today at the European Association for the Study of ...
Tune-401 achieved dose-dependent HBsAg reductions (mean 54% at 0.65 mg/kg) with durable, months-long pharmacodynamics after single dosing on stable nucleos(t)ide analog background. Multiple recipients ...
As part of their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) can establish an infection in liver cells, researchers led by teams at Memorial Sloan ...
Significantly more patients with chronic hepatitis B virus infection achieved functional cure at week 72 after treatment with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results